Contineum Therapeutics, Inc. (CTNM) Stock Analysis

Contineum Therapeutics, formerly Pipeline Therapeutics, is a clinical-stage biotechnology company developing oral small molecules for neuroscience, inflammation, and immunology. It has **no commercial product revenue** and is now primarily a focused bet on wholly owned PIPE-791, an LPAR1 antagonist being tested in the 26-week, approximately 324-patient Phase 2 PROPEL-IPF trial; topline data are expected in mid-2028. The candidate is designed for high receptor occupancy, long residence time, oral bioavailability, and CNS/peripheral penetration, potentially differentiating it from existing IPF drugs associated with gastrointestinal toxicity. The global IPF market was approximately $3.5B in 2023 and is projected to exceed $6.5B by 2032. PIPE-307, licensed to Johnson & Johnson, missed Phase 2 efficacy endpoints in RRMS and MDD, making PIPE-791 the dominant valuation driver. Q2 2026 net loss was $15.15M and diluted EPS was $(0.40), better than the $(0.45) consensus; cash and marketable securities were $236.6M, funding operations into mid-2029. At a $12.56 share price, market capitalization was about $472.5M and enterprise value about $242.5M. The report’s **primary catalyst is the mid-2028 PROPEL-IPF readout**; analysts’ $22.14 consensus target implies 76.3% upside, but clinical downside is severe.